If successful, the cannabis industry would shift from agriculture-based growing into a full 3-D cell culturing platform for growing and expanding cannabinoid-producing cells.
Pluristem Therapeutics, best known for developing novel placenta-based cell therapy products, announced May 6 that it has filed a US provisional patent application titled “Methods and Compositions for Producing Cannabinoids,” which covers the use of Pluristem’s state-of-the-art, proprietary 3-D cell culturing technology for the potential manufacturing of cannabinoid-producing cells.
If successful, this would shift the cannabis industry from agriculture-based growing into a full Good Manufacturing Practice (GMP) 3-D cell culturing platform for growing and expanding cannabinoid-producing cells. Today, manufacturing cannabinoid-producing cells is resource intensive for the number of cells it yields. Pluristem’s process, the company said, is expected to grow these cells in an automated and controlled manner at potentially significantly higher scales with the batch-to-batch consistency of commercial-grade products.